图书简介
The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide “one stop shopping” for the latest information and knowledge of the scientific and engineering advances made over the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies.With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials).Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout.The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field.
Foreword.- Preface.- Introduction.- Section I Background of Structure and Function of Engineered Antibiodies.- Monoclonal Antibodies.- Antibody Drug Conjugates (ADCs), DVDs, BiTES (Bispecfic T Cell Engagers).- Section II Early Stage Analytical, Molecular Assessment and Formulation..- Leveraging the Multi-Attribute Method (MAM) to Improve Biotherapeutic Characterization.- Addressing Product Heterogenetity in ADC Biotherapeutics: Case Studies.- Cutting-Edge Analytical and Structural Methods for Characterization of ADCs.Cutting edge LC and CE-MS Methods for mABs, ACDs, and Bispecfic Antibodies.- Incorporation of Developability, Manufacturability in Therapeutic Antibody Discovery.-Analytical Characterization of Biologics for Candidate Selection and Optimization: Strategies and Case Studies.-Developability Assessment of Bispecific Antibodies: Analytical Platform and Stability Studies.-Method Development and Qualification and Molecular Assessment - Screening for Drug-like properties of DVDs/ADCs.-Solubility and Early Assessment of Stability for Protein Therapeutics (In general and with specific case studies with modalities Duobody).-Screening Antibody Candidates (mAbs) for Manufacturability, Stability, and Deliverability.-Practical Considerations in Screening Excipients for Protein Drugs.-Highly-Automated Procedures for the Assessment of Protein Formulations.-Formulation Design for Biologics in the Age of Lab Automation and Biological Performance Screening.-Pushing Formulation Development into Discovery through Antibody Design and High-Throughput Screening.-An Empirical Phase Diagram/ High Throughput Screening Approach to the Characterization and Formulation of Biopharmaceuticals.-Development of a combination drug product for high protein concentration mAbs: Preformulation, formulation and device – A case study with delivery system.-Formulation and Process development of ADC Drug Products -A Case Study.-Formulation and Device Development Strategies for Fusion Protein, A case study.-Development of a combination drug product for BITEs: Pre-formulation, Analytics, formulation and device – A case study.-Challenges in the Development of Pre-filled Syringes with Device for Biologics from a Formulation and device Points of View.-Section IIIProcess Development.-Scale Down Models for Robust Biologics Drug Product Development.-Engineered antibodies —Understanding Intricacies of Formulation and Freeze Thaw Process.-Development and Scale-up of a Commercial Filtration Process.-Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms Impacting Precision of Low Volume Fill by Peristaltic Pump.-Development and Optimization of Freeze drying Process for Engineered antibodies – Case studies.- Section IVDrug Delivery and Device Development .-Considerations for developing a Biologic in a PFS.-Early Device and Container Closure System Evaluation – A case study for Cartridge.-Prefilled Syringe Technologies for Improving Drug Stability and Reliable PlungerPerformance for Auto-Injectors Applications.-Global Market Trends for Advanced Combination Products –How Innovations can Contribute to Better Patient Outcomes.-Patient Centricity and System Integration as New Drivers of Biologic Drug ProductDesign Strategy.-Drug Delivery and Device Development,. A case study.-Development of a Combination Product : A Case Study.-Development Activities Associated with a One-Way Label Reference for a Devicefor Clinical Use.-Infusion set compatibility and drug delivery challenges of high potency ADCs.- Glossary.- Index.
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐